EUDA Health Holdings Limited

EUDA Health Holdings Limited

EUDA
EUDA Health Holdings LimitedUS flagNASDAQ Capital Market
14.44
USD
-0.46
- -
43.24MMarket Cap
EUDA Health Holdings Limited
EUDA
(NASDAQ Capital Market)

Recent

price

14.44

P/E

ratio

- -

div

yld

- -

ROIC.AI

2020
2021
2022
2023
2024
2025
FRC
19.18
9.85
6.26
3.24
2.47
- -
Revenue per Share
0.38
1.87
-41.37
-8.77
-9.46
- -
Basic EPS, GAAP
-1.05
0.96
-2.54
-2.55
-1.33
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.36
0.52
-3.15
-6.09
-1.37
-2.25
Book Value per Share
-1.82
-0.75
-3.15
-6.09
-1.56
-2.34
Tangible Book Value per Share
- -
- -
1
1
2
- -
Basic Weighted Avg Shares
9
5
4
4
4
7
Sales/Revenue/Turnover
-10.07
-12.28
-156.22
-106.87
-64.31
-35.78
Operating Margin (%)
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
1
-25
-10
-15
-3
Net Income, GAAP
19.26
2.78
- -
- -
- -
- -
Effective Tax Rate (%)
1.98
18.97
-661.06
-270.86
-382.88
-40.65
Profit Margin (%)
-2
-3
-4
-8
-3
-5
Working Capital
- -
- -
- -
- -
- -
- -
LT Debt
- -
1
-4
-7
-3
-4
Total Equity
- -
-58.91
- -
- -
- -
- -
Return on Invested Capital (%)
- -
114.21
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-171.98%
65.92%
Free Cash Flow
- -
-110.61%
17.68%
Net Income, GAAP
- -
-534.68%
-81.94%
Sales/Revenue/Turnover
- -
2.13%
70.04%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
2
1
- -
- -
4
2024
- -
- -
- -
- -
4
2025
- -
- -
- -
- -
7

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-2.39
- -
- -
- -
-8.77
2024
- -
- -
- -
- -
-9.46
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Business
EUDA Health Holdings Limited (EUDA) is a Singapore-based health technology company that operates a digital healthcare ecosystem focused on non-invasive, preventive, and holistic wellness solutions primarily in Southeast Asia, including Singapore, Malaysia, and China. The company provides a proprietary AI-powered platform offering e-triage, teleconsultations with general practitioners, digital medical certificates and prescriptions, urgent care services, specialist referrals, mental health support, physiotherapy, health screenings, and medication delivery through its MyEUDA app; lifestyle and wellness products such as bioenergy cabins, Helixe supplements, Yoroyal holistic wellness items via direct selling, e-commerce, and retail channels, wellness therapies, and membership programs; health plans integrating insurers and providers; and property management services for shopping malls, office buildings, residential apartments, and condominiums. Founded in 2019 by Dr. Kelvin Chen and headquartered at 60 Kaki Bukit Place #03-01, Eunos Techpark, Singapore, EUDA targets individual consumers, corporate clients, and employees seeking affordable, accessible care from wellness prevention to post-treatment aftercare. Recent developments include the May 2024 acquisition of CK Health Plus Sdn Bhd for US$15 million in shares to expand direct-selling of holistic wellness products and license bioenergy cabins to spas and salons; a December 2024 announcement of a potential joint venture with Guangdong Cell Biotech for stem cell therapies and regenerative medicine across Asia; and an August 2025 convertible note issuance completed in November 2025 to enhance liquidity amid ongoing strategic growth in the region's US$740 billion healthcare market.

Company News

  • EUDA Health Subsidiary Melana International Wins SME100 Awards 2026 Singapore

  • EUDA Health Announces Collaboration to Advance an Integrated iPSC Cell Therapy Program for Oncology and Wellness • Targets global distribution for innovative Oncology products

  • EUDA Health Announces Collaboration to Advance an Integrated iPSC Cell Therapy Program for Oncology and Wellness • Targets global distribution for innovative Oncology products

  • EUDA Health Signs Important Tri-Party Memorandum of Understanding with GO POSB Organoids and Shenzhen Inno to Significantly Advance Next-Generation iPSC and NK-TCR Cell Therapies

  • EUDA Health Signs Important Tri-Party Memorandum of Understanding with GO POSB Organoids and Shenzhen Inno to Significantly Advance Next-Generation iPSC and NK-TCR Cell Therapies

  • Phreesia (NYSE:PHR) & EUDA Health (NASDAQ:EUDA) Head-To-Head Review

  • EUDA Health Expands Helixé Product Line with Launch of Regenixé iPSC-Derived Skin Stem Cell Secretome Mask

  • EUDA Health Expands Helixé Product Line with Launch of Regenixé iPSC-Derived Skin Stem Cell Secretome Mask

  • EUDA Health Regains Compliance with Nasdaq Continued Listing Requirements After Receipt of Nasdaq Notification Regarding Minimum Market Value Deficiency

  • EUDA Health Regains Compliance with Nasdaq Continued Listing Requirements After Receipt of Nasdaq Notification Regarding Minimum Market Value Deficiency

  • EUDA Highlights Shenzhen Inno's Approval Under Shenzhen Key Industry R&D Program for TCR-T Cell Therapy Development

  • EUDA Highlights Shenzhen Inno’s Approval Under Shenzhen Key Industry R&D Program for TCR-T Cell Therapy Development

  • EUDA Health Holdings Limited Has Received Notice from Nasdaq that it has Failed to Maintain a Minimum Market Value of its Listed Securities

  • Contrasting EUDA Health (NASDAQ:EUDA) and Outset Medical (NASDAQ:OM)

  • EUDA Announces Reverse Stock Split of its Ordinary Shares

  • EUDA Health Holdings Limited Announces Repurchase and Cancellation of Streeterville Warrant

  • Comparing Hinge Health (NYSE:HNGE) and EUDA Health (NASDAQ:EUDA)

  • EUDA Enters into Convertible Loan Agreement with Shenzhen Inno, Further Expanding Stem Cell Therapy Platform

  • EUDA Health Holdings Limited Announces Amendment to Streeterville Warrant Agreement

  • EUDA Launches Nationwide Stem Cell Extraction, Cryostorage and Clinical Delivery Platform in China with Shenzhen Inno Immune and Wuhan Kaien Hospital